Skip to main content
L

LUYAN PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 002788 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,020 across all filing types
Latest filing 2026-04-20 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002788

About LUYAN PHARMA CO.,LTD

https://www.luyan.com.cn

Luyan Pharma Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive logistics network, providing supply chain management services to healthcare institutions, including hospitals and community clinics. Its product portfolio encompasses a wide range of Western pharmaceuticals, traditional Chinese medicines, and medical equipment. In addition to wholesale distribution, the company maintains a significant presence in the retail pharmacy sector through a chain of drugstores. Luyan Pharma focuses on optimizing healthcare delivery through integrated distribution systems and value-added services, such as third-party logistics and pharmaceutical cold chain management. The organization leverages its regional market leadership to expand its service footprint and enhance the efficiency of the medical supply chain.

Recent filings

Filing Released Lang Actions
2025年度董事会工作报告
Governance Information Classification · 1% confidence The document is titled “2025年度董事会工作报告” and contains detailed descriptions of the board’s composition, meeting schedules, committee charters, governance rule amendments, and oversight activities—i.e., the company’s internal rules, board structure, and governance practices. While it also includes operational performance and outlook (MD&A) sections, the primary focus and title are clearly on the Board of Directors’ work and governance oversight. Therefore, the correct classification is Governance Information (CGR).
2026-04-20 Chinese
关于会计师事务所2025年度履职情况的评估报告
Regulatory Filings Classification · 1% confidence The document is a detailed “evaluation report” by the board on the performance and qualifications of their external auditor for the 2025 fiscal year, as required under Chinese company law, securities law, and Shenzhen Stock Exchange self-regulatory guidelines. It’s neither the company’s annual report (10-K), the actual standalone audit opinion itself (AR), nor a management change, earnings release, or other specific filing type. It is a mandatory regulatory disclosure under listing rules and thus best fits the fallback “Regulatory Filings” category (RNS).
2026-04-20 Chinese
2025年年度报告摘要
Annual Report Classification · 1% confidence The document is titled '鹭燕医药股份有限公司2025年年度报告摘要' (Luyan Pharma Co., Ltd. 2025 Annual Report Summary). It contains key financial data, business highlights, and management discussion for the fiscal year 2025. Although it is a 'summary' (摘要), it is a standard component of the official annual reporting process in the Chinese market, providing substantive financial data and analysis. It is not a mere announcement of a report, but the report summary itself, which falls under the category of an Annual Report (10-K) in the context of financial filings. FY 2025
2026-04-20 Chinese
2025年度内部控制审计报告
Audit Report / Information Classification · 1% confidence The document is a standalone internal control audit report issued by an accounting firm (RSM) on the effectiveness of the company’s financial reporting controls. It contains detailed auditor responsibilities, scope, and opinion sections, and is not an announcement or a full annual report. This matches the ‘Audit Report / Information’ category (code AR).
2026-04-20 Chinese
2025年度内部控制规则落实自查表
Governance Information Classification · 1% confidence The document is a self-inspection checklist (“落实自查表”) of the company’s internal control rules, detailing procedures around internal audit, information disclosure controls, insider trading controls, fundraising controls, related-party transactions, guarantees, major investments, and other governance measures. It is not an earnings release, financial report, proxy, dividend notice, board change, or capital-raising announcement. Rather, it details the company’s internal governance rules and their implementation, matching the description of “Governance Information” (CGR).
2026-04-20 Chinese
关于举行2025年年度报告网上业绩说明会的通知
Investor Presentation Classification · 1% confidence The document is a formal notice that the company will host an online “year‐end performance explanation” session based on its 2025 Annual Report. It is not the Annual Report itself (10‐K) nor a summary of financials (ER), nor a meeting voting result (DVA). Instead, it is an invitation to a presentation for investors to discuss financial results and operations. This aligns with the “Investor Presentation” category (IP).
2026-04-20 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.